All posts by imreal

Flourish Research Expands with Keystone Clinical Acquisition


We are excited to add Keystone to our expanding company, especially given Dr. Verghese’s position as a thought leader in CNS research and the deep relationships Keystone has developed with sponsor customers – Reinhold Schulz, CEO, Flourish Research.

Flourish Research announces the acquisition of Keystone Clinical Studies, adding to the rapidly expanding Flourish enterprise. Keystone, which is in the greater Philadelphia area, is a leader in Alzheimer’s Disease and other CNS research and the addition of the site expands Flourish’s reach in these core areas of research.

Keystone was founded in 2003 by Dr. Cherian Verghese, who will continue to lead the organization. Dr. Verghese, a psychiatrist by training and a founding member of the CNS Summit, has spent more than 30 years focused on conducting clinical research and will assist with Flourish’s future strategy in this therapeutic area. Dr. Verghese and the current management team will continue in their roles at Keystone.

Reinhold Schulz, CEO of Flourish Research, said, “We are excited to add Keystone to our expanding company, especially given Dr. Verghese’s position as a thought leader in CNS research and the deep relationships Keystone has developed with sponsor customers. It has been greatly satisfying to watch the successful integration of our sites over the past few months, and I’m thrilled to continue growing Flourish into a national market leader within the clinical research site space.

Dr. Verghese, of Keystone Clinical, said, “We believe we can add significant value to Flourish by enhancing their CNS capabilities and collaborating with the existing sites. I am looking forward to working with Flourish’s executive team to accelerate growth at Keystone and across Flourish Research.”

About Flourish Research:

Flourish Research is a leading clinical trial organization, created to strategically acquire, integrate, and operate the best clinical trial sites in North America. Flourish started as some of the most recognized trial sites in the industry including Clinical Trials of Texas, Excel Medical Clinical Trials, Clinical Site Partners, Great Lakes Clinical Trials, and Keystone Clinical Studies.

Flourish sites conduct Phase I-IV studies across therapeutic areas where they have deep expertise, including Cardiology/Metabolic Disease/Renal, CNS, Pulmonology, and Vaccines.

Share article on social media or email:

Precision Edge Surgical Products Receives Marmon ‘Automation of the Year’ Award


News Image

“This award is yet another example to our customers and the market of our commitment to remain the industry leader through continued investment in our products, technology, and people,” says Precision Edge President Todd Fewins.

Precision Edge Surgical Products Company, a global leader in contract manufacturing of orthopedic and medical device instruments, is the recent recipient of the “Automation of the Year” award from parent company Marmon Holdings, Inc., a Berkshire Hathaway company.

“This is a direct result of our focused automation and technology strategy that we have been implementing for many years,” says Precision Edge President Todd Fewins. “I am incredibly pleased and could not be prouder of our automation, engineering, and operations teams that continue to successfully execute our mission. This award is yet another example to our customers and the market of our commitment to remain the industry leader by continuing to invest in our products, technology, and people.”

Precision Edge is part of Marmon Holdings, which comprises 11 groups and more than 100 autonomous businesses. Marmon’s Innovation Award recognizes companies and projects that leverage innovation to drive their businesses forward. Precision Edge received this award by implementing five automation projects in 2021 with a significant investment in state-of-the-art equipment. The company previously implemented several other automation projects, and have more scheduled over the next several years with specialized and often custom equipment and technology, designed for high-precision tolerance medical manufacturing.

“It is exciting to be a part of a company that has such a strong commitment to technology advancement that will provide sustainable growth to our business,” says Jordan Verdelli, automation engineer. “It truly gives us a sense of pride and security that we can remain a competitive leader in our markets. Having our employees buy into our culture and automation push has been extremely rewarding. This would not be possible without the entire team’s effort.”

Precision Edge says the timing of executing their automation strategy could not have come at a better time. It not only helps them remain competitive through process improvements, but assists in supplementing the labor challenges facing all industries.

Precision Edge is a member of Colson Medical, LLC, which is majority owned by Marmon Holdings, Inc., a Berkshire Hathaway company. Marmon’s 20,000-plus team members serve diverse industries and markets worldwide.

Share article on social media or email:

Dallas’ Azouz Plastic and Cosmetic Surgery Recognized as 2022 Top Patient Rated Dallas Plastic Surgeons by Find Local Doctors


News Image

“It is such an honor to achieve this recognition. Our goal is always to help patients look and feel their best and achieve natural, lasting results,” says Dr. Solomon Azouz.

Azouz Plastic and Cosmetic Surgery proudly serves patients in the Dallas/Ft. Worth area and from all over the world. The office is located at 7777 Forest Lane – Building C, Suite 802 in Dallas, TX. The clinic’s exceptional ratings and reviews have earned the distinguished 2022 Top Patient Rated Dallas Plastic Surgeon title from Find Local Doctors. Find Local Doctors is a user-friendly online directory, helps consumers connect with skilled physicians in their area who are well-known for their expertise. Dr. David Azouz and Dr. Solomon Azouz are sought out by patients from all over the country and are world-renowned for their expertise in liposuction and the removal of gynecomastia.

Both are fellowship-trained and board-certified plastic and reconstructive surgeons, with international reputations backed by numerous awards spanning multiple decades. At Azouz Plastic and Cosmetic Surgery, the team strives for the most significant improvements in aesthetic appearance, restored functionality and quality of life.

They use innovative procedures and specialized equipment, developed by Dr. David Azouz himself, that have improved on traditional cosmetic surgeries, providing superior results and better patient outcomes. When Solomon Azouz joined, he also brought new techniques, technologies, and customized equipment to the practice.

The team is passionate about providing exceptional care with surgical precision and an eye for artistry. Azouz Plastic and Cosmetic Surgery delivers an extensive range of cosmetic procedures, offering natural and beautiful results.    Azouz plastic surgery specializes in plastic surgery of the face, chest, and body. Surgical options are available for ear, eyelid and nose plastic surgery, facelift, labiaplasty, cosmetic surgery, male surgery, breast implant removal, skin growth/scar removal and transgender top surgery.

“It is such an honor to achieve this recognition. Our goal is always to help patients look and feel their best and achieve natural, lasting results,” says Dr. Solomon Azouz.

More About Azouz Plastic and Cosmetic Surgery:

Azouz Plastic and Cosmetic Surgery includes two board-certified plastic surgeons, recognized as the best in their field in Dallas, Texas. Both Dr. David Azouz, who has decades of experience, and Dr. Solomon Azouz, who is a Mayo-trained plastic surgeon, are compassionate and talented doctors committed to providing the best possible results. They use superior and innovative techniques to restore and reshape the cosmetic appearance of their patients.

For more information or to schedule a consultation, please contact Azouz Cosmetic and Plastic Surgery by calling (972) 702-8888 or visiting the website at http://www.drazouz.com.

Share article on social media or email:

Yes Becomes A Part of the Virgin Pulse Partner Ecosystem


Virgin Pulse and Yes Health Logo

Yes Health is now part of the Virgin Pulse partner ecosystem.

“By offering Yes Health to their populations, employers using Virgin Pulse are providing more than just a benefit,” said Alex Petrov, founder and CEO of Yes Health.

Yes Health, a leading digital health provider focused on weight loss, diabetes prevention and concierge health coaching, today announced it is now part of the Virgin Pulse partner ecosystem. Recognized by the U.S. Centers for Disease Control (CDC), the Yes Health program is an all-mobile weight loss and diabetes prevention solution that supports people with making healthier decisions at the exact time they need it. The program is now available to Virgin Pulse clients as part of its curated ecosystem, available via its Homebase for Health® platform addressing health, wellbeing, and navigation needs.

“Health plans and employers need digital health solutions that are convenient, keep people engaged, and are enjoyable to use, which is why Yes Health has been the perfect tool for organizations that want to inspire healthy lifestyles among their populations. Now, through the Virgin Pulse partner ecosystem, we can reach millions more people across thousands of organizations,” said Alex Petrov, founder and CEO of Yes Health. “By offering Yes Health to their populations, employers using Virgin Pulse are providing more than just a benefit. They are providing each person with a team of experts supported by the latest technology who empower them each and every day to set and achieve their health goals.”

Yes Health blends artificial intelligence (AI) with in-the-moment human coaching to inspire healthy behavioral change. Members virtually engage with health coaches on their smartphones at any time and are provided with a personalized, evidence-based plan curated by Yes Health’s team of dietitians, nutritionists, fitness experts and psychologists. Members also can leverage Yes Health’s proprietary machine-vision technology where they take pictures of their meals to get AI-assisted guidance on how to make them healthier.

According to the CDC, more than 40 percent of the U.S. population is considered obese, a serious and costly condition that can lead to other chronic diseases like diabetes. The medical costs for obesity are estimated to be as high as $210 billion annually, including nearly $62 billion in Medicare and Medicaid spending alone. For employers, studies have suggested that overweight employees create approximately $73 billion in medical costs a year and generate much higher rates of medical and worker’s compensation claims than healthier employees.

Companies can select Yes Health from a curated collection of partners as part of the Virgin Pulse partner ecosystem, which helps employers close gaps in care across more than 20 health and wellbeing categories while addressing the most common and costly health concerns. All partner solutions are seamlessly integrated and accessible through Virgin Pulse’s Homebase for Health platform, optimizing program utilization and the user experience.

About Yes Health

Yes Health is the first fully CDC-recognized, all-mobile diabetes prevention program with on-demand coaching designed to empower people everywhere to start living healthier, happier lives. Its team of physicians, health coaches and engineers has created a high-engagement, lifestyle-change platform that’s low-cost, easy to follow and successful. With its best-in-class diabetes prevention, weight loss, and healthy lifestyle programs, Yes Health provides its platform to payers, providers and self-insured employers, helping them achieve a higher ROI on their condition management and wellness programs. Yes Health helps people take charge of their health – and have fun doing it – by developing healthy habits that last a lifetime. For more information, visit http://www.yeshealth.com.

Share article on social media or email:

Dr. John Jaquish Discusses 4 Ways Variable Resistance Training Counters Menopause Symptoms


WSJ Bestselling book, Weightlifting is a Waste of Time – So is Cardio

It’s safe to say most women want to be leaner and healthier, and not fatter and more prone to heart problems. Variable resistance is a proven method of achieving these goals. John Jaquish, Ph.D.

Suddenly, seemingly out of nowhere, menopause symptoms can strike women, resulting in uncontrollable weight gain, hot flashes, night sweats, exhaustion, and muscle and bone density loss. Dr. John Jaquish, scientist, inventor, and author of the WSJ Bestselling book, Weightlifting is a Waste of Time – So is Cardio explains how variable resistance exercise is a highly effective approach for building muscle, losing fat, and producing a number of other essential benefits that can help women overcome menopause and post-menopausal symptoms.

Variable resistance exercise utilizes elastic bands to vary the resistance (tension on the muscle) as we perform an exercise. The resistance is lightest at the beginning of the repetition and heaviest at the end of the repetition. Variable resistance band training places less stress on joints (where we are weakest) and more stress at points in the range of motion where we are strongest, maximizing workout effectiveness and minimizing the risk of injury.

“A 2018 study of 38 post-menopause women showed training with variable resistance not only significantly lowered weight and waist circumference but also improved cardiovascular profiles and cholesterol indicators. The control group that didn’t do any exercise over the same one-year period showed significant increases in their weight and waist circumference,” said Dr. Jaquish.

Variable resistance offers many health benefits and here are five that particularly help women experiencing menopause and post-menopause symptoms:

  • Boosts Metabolism. It is not only the best way to enhance body composition but the more muscle, the faster the metabolism This means burning calories at a greater rate, even by just breathing.
  • Reduces Risk of Heart Disease. In the United States, heart disease is the leading cause of death for women but also the most preventable. Variable resistance improves heart health by decreasing blood pressure and reducing plasma triglycerides. Furthermore, strength training may be more beneficial for heart health than dynamic or cardio exercise.
  • Promotes Mental Health. A meta-analysis of 33 clinical trials found that strength training corresponds with a reduced risk of depression. Resistance training also reduces instances of anxiety.
  • Builds Self-Esteem. When women are physically stronger, they’re more confident, independent, and resilient. A 2013 study found that women who strength train have a more positive body image and report greater fulfillment in life resulting in an improved sense of self-worth.


“It’s safe to say most women want to be leaner and healthier, and not fatter and more prone to heart problems. Variable resistance is a proven method of achieving these goals. But the real takeaway is, women can effectively strength train with little to no risk of injury and get these benefits with variable resistance,” said Dr. Jaquish.

The book is packed with research, studies, and details on the better way to have a strong lean body and good health.

For more information about Dr. Jaquish and to order the book Weightlifting is a Waste of Time – So is Cardio, visit doctorj.com

About John Jaquish, PhD

Scientist, inventor, and author John Jaquish, PhD. has spent years researching and developing improved approaches to health. He is the inventor of the bone density-building medical technology OsteoStrong and the creator of the variable resistance X3 exercise system for accelerated muscle development. Dr. Jaquish’s methods are used in training the world’s most elite athletes, including the Miami Heat, various NFL and NBA players, MMA champions, and members of the US Olympic team. His book, Weightlifting is a Waste of Time – So is Cardio, explains his non-conventional approach to human physiology and is a WSJ Bestseller

Share article on social media or email:

IaC Security Leader oak9 Launches Free Community Edition to Make Cloud Native Security More Accessible


oak9's Security as Code platform dashboard for Infrastructure as Code (IaC) and deployed cloud workloads

oak9’s Security as Code Platform Dashboard

oak9’s Community Edition is designed to help customers secure cloud native infrastructure easily and quickly while removing costs and feature limitations as barriers to entry for cloud native security

oak9, developer-first Infrastructure as Code (IaC) security leader, today announced the launch of a free Community Edition of its Security as Code software platform designed to make cloud native security more accessible and easy to use.

Community Edition is an all-access, free edition of oak9’s leading Security as Code Software Platform. No credit card is required, no software installation is necessary, and it comes with no commitments and no expiration. In less than five minutes, customers can sign up and secure their cloud native infrastructure to understand where security and compliance gaps exist, the criticality of each gap based on the application’s business context, why they were flagged, and exactly how to fix them.

“A customer of ours was recently trying to meet HITRUST compliance and had a small team with very limited security resources – an ongoing problem in the industry,” said Om Vyas, oak9’s co-founder and Chief Product Officer. “They built Terraform using publicly available modules and their Kubernetes clusters were not encrypting disks for their business-critical application. Within minutes of using oak9, they realized encryption-at-rest was required, and leveraged oak9’s automated remediation to address both encryption and related key management considerations. We were able to bring their cloud architecture up to HITRUST compliance quickly.”

From sign-up to automated remediation directly in developer workflows, oak9’s Community Edition is designed to help customers secure cloud native infrastructure easily and quickly while removing costs and feature limitations as barriers to entry for cloud native security.

Community Edition is built for developers, DevOps engineers, security engineers, architects, and software engineers who write and build Infrastructure as Code (IaC). These individuals are those who may be interested in IaC Security and don’t know where to start, want to understand why vulnerabilities are important and what’s going to happen if they’re not fixed, and know they have vulnerabilities, but could use help on how to fix them.

oak9 helps them understand not only how to secure the gap, but whether the risk is viable, what happens if they don’t fix it, and why it’s important. oak9 continues to deliver on its promise of simplifying cloud native infrastructure security and is an excellent fit for high-tech companies, healthcare, finance, and retail companies using Infrastructure as Code (IaC) or those wanting to learn more about IaC.

Learn more about oak9’s Community Edition and get started on your journey here.

About oak9

oak9 secures cloud native infrastructure for developers. oak9 Security as Code continuously finds, analyzes, and remediates security and compliance issues in real-time, as infrastructure as code (IaC) changes – the only software solution automating cloud native security across the entire software development lifecycle. oak9’s proprietary Security as Code (SaC) blueprints support 20-plus compliance standards out-of-the-box including HIPAA, HITRUST, PCI, SOC2 and ISO27001. oak9’s open-sourced Security as Code also enables security engineers to extend oak9 security blueprints for additional guard rails. Headquartered in Chicago, oak9 is a Built in 2022 Start-up to Watch with key investors Menlo Ventures, HPA, Cisco Investments, and Morgan Stanley’s Next Level Fund. oak9 partners with HashiCorp, AWS, and Microsoft, and actively supports the Cloud Security Alliance (CSA) and Open Web Application Security Project (OWASP). Keep in touch with oak9 on LinkedIn, Twitter, Youtube, and TikTok, or visit oak9.io.

***

All trademarks are the property of their respective owners in the U.S. and other countries.

Share article on social media or email:



BestRx Pharmacy Software Receives 2022 Surescripts White Coat Award


BestRx Receives 2022 Surescripts White Coat Award for Highest Accuracy

BestRx Receives 2022 Surescripts White Coat Award for Highest Accuracy

“BestRx has remained committed to developing software solutions to help independent pharmacies operate and better care for their community,” says Hemal Desai, President of BestRx. “This includes providing pharmacies with a way to process electronic prescriptions quickly and accurately.”

BestRx has received the 2022 Surescripts White Coat Award™ for Highest Accuracy, the healthcare industry’s premier recognition for leaders in e-prescription accuracy.

BestRx, a pharmacy technology vendor, is among the top winners from across the Surescripts Network Alliance® who met the highest standards for prescription accuracy and patient safety.

BestRx knows that patient health and safety is at the heart of everything a pharmacy does. That’s why we build our pharmacy software around simplifying their prescription workflows. By streamlining the way pharmacies receive and process scripts electronically, BestRx helps to ensure their compliance and accuracy.

“Since our inception, BestRx has been focused on developing software solutions that help independent pharmacies operate more efficiently and ultimately better care for their community,” says Hemal Desai, President of BestRx. “Software integrations, like the one we have with Surescripts, enable us to do just that. Our pharmacy management software is designed with the pharmacy in mind, providing a simple, effective way for them to receive and process electronic prescriptions quickly and accurately.”

The 2022 Surescripts White Coat Award recognized winners in three categories:


  • The Highest Accuracy award recognizes the best overall accuracy score.
  • The Structured & Codified Sig Champion award recognizes organizations making the best use of the Structured & Codified Sig field.
  • The RxChange Champion award highlights organizations successfully advancing the RxChange transaction.

“We are incredibly proud of this year’s White Coat Award winners, who are among the highest achieving to date,” said Frank Harvey, Chief Executive Officer of Surescripts. “It is a tremendous point of pride that they are among our Surescripts Network Alliance, optimizing the performance of the Surescripts network and leading the transformation of healthcare across the country.”

White Coat Award winners are evaluated based on data provided by Surescripts Sentinel®, an automated system that monitors electronic prescriptions and delivers insights to pharmacies, health systems and technology vendors. In 2021, the Surescripts Network Alliance saw a 10% increase in the aggregated Quality Index Score for electronic prescriptions across the network—a 200% improvement since 2016.

Visit Surescripts.com to learn more about the Surescripts White Coat Award.

About BestRx

Founded in 1985, BestRx is proud to still be a family business. Our goal from day one has been to give independent pharmacies the tools needed to run their business more efficiently and profitably while advancing the level of patient care. BestRx prides itself on its intuitive, easy-to-use platform, first-to-market features, and unparalleled customer service. BestRx is committed to ongoing innovation, ensuring they’ll always be at the heart of growth. Visit http://www.bestrx.com to learn more.

Share article on social media or email:

Mark Cuban Cost Plus Drug Company and VIVIO team up to help employers and health plans stop overpaying for specialty drugs


“We seek to partner with other like-minded innovators to drive meaningful change to an industry that desperately needs it but doesn’t want it. Our relationship with Cost Plus Drugs allows our customers to stop overpaying for drugs, and that’s an important part of our mission.” Pramod John, VIVIO CEO

VIVIO, a public benefit corporation reinventing the use of drug trial data in care delivery, announces a relationship with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to acquire specialty drugs for less. Since Cost Plus Drugs and VIVIO are Public Benefit Corporations (PBCs), improving public health by lowering the cost of healthcare is as important as the bottom line.

America spends $500 Billion a year on prescription drugs. Less than 2% of prescriptions are written for ‘specialty’ drugs, but these account for $250 Billion, half of America’s total drug spend. Clinical trials and real-world evidence demonstrate that suboptimal drugs are being prescribed frequently. This means we pay for drugs that often don’t work because no one is asking the question, what do these drugs do? VIVIO’s team of clinicians and researchers match drug trial evidence to individual patient data, which improves outcomes, reduces side effects, and lowers member, employer, and health plan drug costs.

“The event that led to finalizing the collaboration between VIVIO and Cost Plus Drugs is as horrific as it is incredibly uplifting,” said Mark Cuban. “Last week I was contacted by a friend from Indiana University who mentioned that a mutual friend was in a dire situation. The mutual friend was quoted a price of $3,000 per month for a generic specialty drug called droxidopa. He asked if Cost Plus Drugs could find an affordable source of the medication.”

The Cost Plus Drugs team went to work immediately, says Cuban. Within a week, Cost Plus Drugs had sourced the same medication at a price of $75 for a three-month supply, less than 1% of the cost Cuban’s friend was paying.

“I mentioned this in an interview with Trevor Noah on The Daily Show and this caught the attention of Pramod John, the CEO of VIVIO. As it turns out, VIVIO also has patients taking droxidopa. I am excited to say our relationship was finalized in a matter of days,” said Cuban. “Now VIVIO patients will have access to pay far less for droxidopa and many other medications when using Cost Plus Drugs. I am so looking forward to us working together to benefit patients everywhere!”

“As a Public Benefit Corporation, the interests of VIVIO, our patients, and our employer and health plan customers must be aligned. They want better outcomes and lower costs, and so do we. Unlike PBMs, we don’t have a formulary or own any pharmacies or provider services. Instead, our sole business is to use data to ensure drugs are working for each patient and are acquired at the lowest cost,” says Pramod John, VIVIO CEO. “We seek to partner with other like-minded innovators to drive meaningful change to an industry that desperately needs it but doesn’t want it. Our relationship with Cost Plus Drugs allows our customers to stop overpaying for drugs, and that’s an important part of our mission.”

“A foundational principle for Cost Plus Drugs and VIVIO is fairness and transparency,” says Alex Oshmyansky, CEO of Cost Plus Drugs. “It is never fair to pay $3K for a drug that’s available for $21 or to pay for a drug without the data supporting its use. This causes inflation, premium increases, and a bloated, inefficient $4.2 Trillion health system.”

About VIVIO Health, a Public Benefit Corporation

VIVIO Precision Care™ uses data to fix the big unsolved problem of paying for expensive drug therapies that don’t work for members while causing side effects. VIVIO helps self-insured employers and health plans ensure their members are on the right drugs while not overpaying for them. In 2021, VIVIO customers’ specialty drug spend was 65% lower than national benchmarks.

About Mark Cuban Cost Plus Drug Company, a Public Benefit Corporation

Cost Plus Drugs aims to change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries nearly 1,000 prescription products, delivered by mail to thousands of happy customers every day. Cost Plus Drugs works with health plans, managed-care organizations, pharmacy benefits managers (PBMs), and self-insured employers to bring these same savings to employer-sponsored benefit plans nationwide.

Share article on social media or email:

Diagnostic Device Executive Joins NDA Partners as Expert Consultant


News Image

Mr. Clark brings significant experience to our firm in the development and commercialization of diagnostics devices.

NDA Partners’ General Manager, Eric Fish, announced today that Kevin Clark, a diagnostic device executive, has joined the firm as an Expert Consultant. Mr. Clark has extensive experience in business development and commercialization of diagnostic devices including ELISA and IFA laboratory testing systems.

Mr. Clark is founder of ImmunoVision, Inc. (subsidiary of IVAX Diagnostics, Inc.), where he served as COO and CEO. In 2011, IVAX merged with ERBA Diagnostics, Inc. and he served as CEO and President of the new company. Following his role at ERBA, Mr. Clark joined NOWDiagnostics as CEO where he led product development and commercialization efforts for the company’s point-of-care (POC) testing platform.

Throughout his career, Mr. Clark built a diagnostic company which went public, served in COO and CEO roles, managed multinational business operations, sourced investors, and brokered mergers and acquisitions, all while developing, manufacturing, and selling products that required FDA approval. He has successfully achieved marketing approval for 126 products through the regulatory approval process and scaled diagnostic companies from inception to lucrative exit on a global scale.

According to Dr. Alberto Gutierrez, Manager of NDA Partners’ diagnostics device practice, “Mr. Clark brings significant experience to our firm in the development and commercialization of diagnostics devices. His expertise will be valuable to companies navigating the regulatory approval process and scaling up their manufacturing operations.”

Mr. Clark received his master’s degree in immunology and a bachelor’s degree in pre-veterinary studies from the University of Arkansas. He has served as Chairman, Executive VP and Founding Member of the Arkansas Biotechnology Association, and on the Boards for the University of Arkansas Technology Development Foundation and Arkansas BioVentures. He currently serves on the Board for Biomedical Engineering College and the Entrepreneurial Board for the University of Arkansas, Sam Walton College of Business.

About NDA Partners

NDA Partners, a ProPharma Group company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.

Contact

Eric Fish, General Manager

Office: 540-738-2550

FishEric@ndapartners.com

Share article on social media or email:

New Release of Genedata Expressionist For Innovative Characterization and Automated Quality Monitoring of Next-Generation Biotherapeutics


News Image

The new characterization functionalities deliver deeper insights, enabling our industry partners to ensure the safety and efficacy of their drugs, while novel automation capabilities for CQA monitoring accelerate and streamline processes throughout R&D. Othmar Pfannes, Ph.D., CEO, Genedata

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Expressionist® 16.5, the latest version of its platform for streamlining and automating mass spectrometry data workflows, from early discovery to late-stage development. Genedata Expressionist 16.5 takes characterization and quality monitoring of biotherapeutics and oligonucleotides to the next level by enabling leading biopharma companies to fully leverage the potential of mass spectrometry data in their R&D workflows, irrespective of the instrument or technology applied.

Genedata Expressionist 16.5 introduces top-down protein sequencing using tandem mass spectrometry (MS/MS) to address the growing need to rapidly analyze expected drug proteoforms—for example, in biosimilar assessment—on an industrial scale. This release further enhances the established characterization workflows built into Genedata Expressionist for the identification of multiple clipping events in biotherapeutics. Smart filters reduce the number of false-positive clipping results that are typically obtained in such analyses, significantly reducing the time required to review large data sets. These new capabilities enable scientists working in biopharma to not only meet current and emerging analytical challenges, but also allow them to keep pace with ever-increasing molecular complexity and process scale.

As the industry leader in end-to-end automation of MS data analysis, Genedata Expressionist now offers automated product quality monitoring of emerging modalities—such as therapeutic oligonucleotides. Expert users can easily define critical quality attributes (CQAs) of any molecular structure and monitor them using routine automated processes. The generated results can be verified using a new interactive CQA review process, enabling users to leverage and integrate their knowledge into the overall automated workflow. With the introduction of these novel product quality monitoring capabilities, this release further cements the position of Genedata Expressionist as the platform of choice for the automation of MS data analysis across all stages of drug discovery, development, and manufacturing.

“The inherent complexity of innovative biotherapeutics necessitates comprehensive characterization and robust product quality assessment. The new characterization functionalities in Genedata Expressionist 16.5 deliver deeper insights, enabling our industry partners to ensure the safety and efficacy of their drugs, while novel automation capabilities for CQA monitoring accelerate and streamline processes throughout R&D,” stated Othmar Pfannes, Ph.D., CEO of Genedata. “We will continue to work closely with leading biopharma companies to deliver the automated data processing solutions required to develop next-generation therapies.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

http://www.genedata.com | LinkedIn | Twitter | YouTube

________________________________________

Contact

Allison Kurz

Genedata

Public Relations

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email: